జర్నల్ ఆఫ్ క్లినికల్ అండ్ ఎక్స్‌పెరిమెంటల్ ట్రాన్స్‌ప్లాంటేషన్

నైరూప్య

HLA Typing and Hematopoietic Stem Cell Transplantation Outcome: Review

Maryam Behfar

For many patients suffering from hematologic diseases, hematopoietic stem cell transplantation (HSCT) is a curative procedure. The plan is to use healthy hematopoietic stem cells from an HLA-compatible donor to replace the patient’s immune and hematopoietic systems. For HSCT to be successful, genetic differences between the donor and recipient, particularly at HLA loci are crucial. Acute and chronic graft - versus - host diseases (GVHD) continue to be major causes of morbidity and mortality after HSCT despite improvements in genetic characterisation, immuno-suppressive medications, and supportive treatment. Along with genetic differences and GVHD, the source of the stem cells, conditioning regimens, and infection problems are linked to the success of HSC. Other donorrelated factors, such as gender, age, and the presence or absence of cytomegalovirus (CMV) antibodies. HSCT outcomes may also be influenced by and ABO incompatibility, whose individual contributions have been investigated with varying degrees of success.